Public drug coverage now provides eligible adults access to CRYSVITA, the only approved treatment for X-linked hypophosphatemia (XLH), a lifelong progressive disease TORONTO, May 06, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin Canada, a wholly owned subsidiary of Kyowa Kirin Inc., is pleased to announce that CRYSVITA® (burosumab injection) is now publicly funded for eligible adults living with X-linked hypophosphatemia in Ontario, British Columbia, Saskatchewan, and Alberta, as well as through the federal Non-Insu ...